Bioventix (BVXP)

 

BVXP Share PerformanceMore

52 week high2,725.0 06/09/17
52 week low1,075.0 04/10/16
52 week change 1,337.5 (118.89%)
4 week volume56,241 29/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: BIOVENTIX PLC 1b. Please indicate if the issuer is a non-UK issuer (please ...

A small-cap pharma still smashing City forecasts

This hugely lucrative AIM drug company has wowed its cheerleaders in the City again. David Brenchley asks whether its i...

Bioventix ahead of forecasts

Bioventix expects revenues for the year ended 30 June to be marginally in excess of 7m (2015-16: 5.5M). It said that since the ...

Trading Update, Notice of Results & AGM

Bioventix plc (?Bioventix? or the ?Company?) Trading Update, Notice of Results and AGM Trading Update Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, announces a trading update. The Board is pleased to report that revenues for the financi...

Holding(s) in Company

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: BIOVENTIX PLC 1b. Please indicate if the issuer is a non-UK issuer (please ...

Holding(s) in Company

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: BIOVENTIX 1b. Please indicate if the issuer is a non-UK issuer (please mark...

10 of the best-quality companies on AIM

With a sharp rise in AIM companies delisting due to Nomad resignations, Stockopedia's Ben Hobson finds 10 small caps wit...

Bioventix to get royalties from Siemens troponin test

Bioventix has described the launch of a new test by Siemens for troponin, a key biomarker used in heart attack diagnostic...

Fundamental DataMore

P/E ratio35.596
EPS69.18
Dividend yield1.726 %

Latest discussion posts More

  • Re: Trading update

    Revenue to 30th June 2017 is expected to be ?marginally in excess? of #7m and that due to the cost base ?follow a similar shallow trajectory as in previous years?, both ...
    5-Sep-2017
    charlie51
  • Re: Trading update

    SM, Quite right, as long as they keep increasing revenue, profits and dividend, the share price is a bit of an irrelevance to me - at least till it starts getting to be too ...
    4-Sep-2017
    Hardboy
  • Re: Trading update

    Hradboy " though it will still only be a yield of around 2.5%." Just think what the yield would be against your original purchase price! SM
    4-Sep-2017
    smilingmickey1

Users' HoldingsMore

Users who hold Bioventix also hold..
IQE20%
BURFORD CAP LD19%
LLOYDS GRP.19%
XLMEDIA19%
GLAXOSMITHKLINE18%

Codes & Symbols

ISINGB00B4QVDF07
SymbolsBVXP, LSE:BVXP, BVXP.L, BVXP:LN, LON:BVXP, XLON:BVXP